Marco Meglio, Editor for NeurologyLive, has been with the team since October 2019. Follow him on Twitter @marcomeglio1 or email him at mmeglio@neurologylive.com
Lacosamide Provides Benefit as Second-Line Treatment for Refractory Trigeminal Neuralgia
May 21st 2023To date, in the largest series of patients treated with lacosamide after first-line treatment failure, pain relief was achieved in 66% of patients, with a relatively low proportion of mild adverse events.
NeuroVoices: Nancy Foldvary-Schaefer, DO, FAAN, on the Crossover Between Sleep and Epilepsy
May 17th 2023The director of the Sleep Disorders Center and staff in the Epilepsy Center at Cleveland Clinic provided perspective on the current state of sleep and epilepsy research, including the role of postical generalized EEG suppression as a biomarker for SUDEP.
Soticlestat Decreases Motor Frequency in CDKL5 Deficiency Disorder, With Benefits in Dup15q Syndrome
May 16th 2023Improvements seen in patients with CDD during the 12-week maintenance period of the study were similar to that observed in a recent trial of ganaxolone, the first FDA-approved therapy for CDD.
Higher Vascular Risk Indirectly Predicts Lower Plasma Aß42/40 in APOE ɛ4 Carriers
May 16th 2023Regardless of highly different demographics and smaller sample size, the association between amyloid in the brain and plasma was influenced by overall vascular risk score, and was only consistently observed in APOE ɛ4 carriers.
Activated Microglia Contribute to Neurofilament Light Levels in Multiple Sclerosis
May 11th 2023The strongest associations observed in the study were between microglial activation at the rim of chronic T1 hyperintense lesion and in the perilesional normal appearing white matter and serum neurofilament light.
NeuroVoices: Sean Pittock, MD, on How Ravulizumab’s Effectiveness Speaks to Progress in NMOSD
May 10th 2023The director of the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology provided perspective on a phase 3 study of patients with NMOSD in which no relapses were recorded while on ravulizumab.